Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514824 · ClinicalTrials.gov registry record · Phase 1
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02514824: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT02514824 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02514824, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. \- The name of the study intervention involved in this study is: MLN0128.
Primary Outcome
The MLN01283 MTD is determined by the number of participants who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached but the highest dose received may be the Recommended Phase II Dose (RP2D).
Interventions
- DRUG MLN0128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
What the finished NCT02514824 record still lists
NCT02514824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which MLN0128 is the first listed.
NCT02514824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02514824 about?
NCT02514824 is a clinical study titled "MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma". This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. \- The name of the study intervention involved in this study is: MLN0128.
What is the current status of trial NCT02514824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-10. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02514824?
The interventions under investigation include: MLN0128 (DRUG).
Who is sponsoring clinical trial NCT02514824?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02514824's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia